{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:28:12Z","timestamp":1760149692693,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, rare, complement-mediated hemolytic anemia. PNH can be associated with marrow failure and thrombophilia. We present a clinical report of splenic vein thrombosis in a patient with classic PNH. A 41-year-old male with classic PNH, na\u00efve to complement inhibitor therapy, developed splenic vein thrombosis as a major adverse effect after vaccination protocol to prevent meningococcal disease. We also report anticoagulant and eculizumab treatment outcomes. In PNH patients, vaccination should be monitored to prevent major outcome events, like vaccine-induced thrombosis. Eculizumab proves effective for treating intravascular hemolysis and preventing more thrombotic events. The potential protective role of eculizumab on controlling complement activity and consequent inflammation may help the patient to not experience breakthrough hemolysis when infected with SARS-CoV-2. Extravascular hemolysis remains present, but new molecules are being studied to inhibit proximal complement and there is a good health prospective for PNH patients.<\/jats:p>","DOI":"10.3390\/reports6030042","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:57:17Z","timestamp":1694159837000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paroxysmal Nocturnal Hemoglobinuria: A Case Report in a Pandemic Environment"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-3186","authenticated-orcid":false,"given":"Vanda","family":"Peixoto","sequence":"first","affiliation":[{"name":"Chemical and Biomolecular Sciences, School of Health, Polytechnic Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Center for Translational Health and Medical Biotechnology Research (TBIO), Polytechnic Institute of Porto, 4200-465 Porto, Portugal"}]},{"given":"Ana","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Center of S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Center of S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-4811","authenticated-orcid":false,"given":"M\u00f3nica","family":"Vieira","sequence":"additional","affiliation":[{"name":"Chemical and Biomolecular Sciences, School of Health, Polytechnic Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Center for Translational Health and Medical Biotechnology Research (TBIO), Polytechnic Institute of Porto, 4200-465 Porto, Portugal"},{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9920-936X","authenticated-orcid":false,"given":"Cristina","family":"Prud\u00eancio","sequence":"additional","affiliation":[{"name":"Chemical and Biomolecular Sciences, School of Health, Polytechnic Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Center for Translational Health and Medical Biotechnology Research (TBIO), Polytechnic Institute of Porto, 4200-465 Porto, Portugal"},{"name":"Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories","volume":"112","author":"Mary","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcmd.2017.03.013","article-title":"Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status","volume":"65","author":"Yenerel","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/ehm.09.35","article-title":"How do PIG-A mutant paroxysmal nocturnal hemoglobinuria stem cells achieve clonal dominance?","volume":"2","author":"Brodsky","year":"2009","journal-title":"Expert Rev. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood.V79.6.1447.1447","article-title":"The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria","volume":"79","author":"Ploug","year":"1992","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V82.4.1192.1192","article-title":"Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria","volume":"82","author":"Wiedmer","year":"1993","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1538-7836.2007.02379.x","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria: Sites, risks, outcome. An overview","volume":"5","author":"Ziakas","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2011.04562.x","article-title":"Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"10","author":"Muus","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gralinski, L.E., Sheahan, T.P., Morrison, T.E., Menachery, V.D., Jensen, K., Leist, S.R., Whitmore, A., Heise, M.T., and Baric, R.S. (2018). Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio, 9.","DOI":"10.1128\/mBio.01753-18"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study","volume":"28","author":"Annane","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1743-422X-5-47","article-title":"Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review","volume":"5","author":"Mourtzoukou","year":"2008","journal-title":"Virol. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/1752-1947-4-334","article-title":"Hemolytic anemia due to acute cytomegalovirus infection in an immunocompetent adult: A case report and review of the literature","volume":"4","author":"Taglietti","year":"2010","journal-title":"J. Med. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s100960050282","article-title":"Association between Primary Cytomegalovirus Infection and Severe Hemolytic Anemia in an Immunocompetent Adult","volume":"18","author":"Leclercq","year":"1999","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2141.1996.00288.x","article-title":"Cytomegalovirus-induced thrombocytopenia and haemolysis in an immunocompetent adult","volume":"92","author":"Breed","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2004.04992.x","article-title":"Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays","volume":"126","author":"VMoyo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood-2003-01-0009","article-title":"Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)","volume":"102","author":"Hall","year":"2003","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2019003812","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"137","author":"Brodsky","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.bcmd.2021.102641","article-title":"Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination","volume":"93","author":"Jarrah","year":"2022","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1182\/blood.2021011548","article-title":"COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria","volume":"137","author":"Gerber","year":"2021","journal-title":"Blood"},{"key":"ref_26","first-page":"122","article-title":"Paroxysmal nocturnal hemoglobinuria diagnosed after influenza vaccine: Coincidence or consequence?","volume":"16","author":"Green","year":"2014","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.vaccine.2018.11.045","article-title":"Causal relationship between immunological responses and adverse reactions following vaccination","volume":"37","author":"Nakayama","year":"2019","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/14760584.2023.2222015","article-title":"A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)","volume":"22","author":"Marshall","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0736-4679(99)00135-3","article-title":"The C-reactive protein","volume":"17","author":"Clyne","year":"1999","journal-title":"J. Emerg. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1024\/0040-5930\/a000384","article-title":"Die Milz bei nicht-malignen h\u00e4matologischen Erkrankungen","volume":"70","author":"Wuillemin","year":"2013","journal-title":"Ther. Umsch."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2022.08.002","article-title":"Potential mechanisms of vaccine-induced thrombosis","volume":"105","author":"Marietta","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-0-387-78952-1_7","article-title":"Platelet Mediated Complement Activation","volume":"632","author":"Peerschke","year":"2008","journal-title":"Curr. Top. Complement II"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2141.1995.tb05371.x","article-title":"Activated platelets in paroxysmal nocturnal haemoglobinuria","volume":"91","author":"Gralnick","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/bph.15476","article-title":"Complement, inflammation and thrombosis","volume":"178","author":"Rawish","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ajh.21506","article-title":"Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Emadi","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"ref_37","first-page":"16271","article-title":"Paroxysmal nocturnal hemoglobinuria: Advances in the understanding of pathophysiology, diagnosis, and treatment","volume":"132","author":"Szlendak","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"198070","DOI":"10.1016\/j.virusres.2020.198070","article-title":"COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking","volume":"286","author":"Magro","year":"2020","journal-title":"Virus Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.clim.2020.108555","article-title":"Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19","volume":"219","author":"Laurence","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_40","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"108598","DOI":"10.1016\/j.clim.2020.108598","article-title":"Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy","volume":"220","author":"Mastellos","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/JIR.S267280","article-title":"Role of IFN and Complements System: Innate Immunity in SARS-CoV-2","volume":"13","author":"Shibabaw","year":"2020","journal-title":"J. Inflamm. Res."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/6\/3\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:47:14Z","timestamp":1760129234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/6\/3\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["reports6030042"],"URL":"https:\/\/doi.org\/10.3390\/reports6030042","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}